Summary of Study ST001976

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001255. The data can be accessed directly via it's Project DOI: 10.21228/M8GT41 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST001976
Study Title	Anti-oxidation metabolism measurement in mammalian cells and tissues by quantitative LC/MS method (III)
Study Summary	Anti-oxidative metabolism measurement in mouse CSF by quantitative LC/MS method of mouse CSF at 24H of MTX treatment, for either control GFP or SOD3-overexpressing ChP mice.
Institute	Boston Children's Hospital, Harvard Medical School
Last Name	Petrova
First Name	Boryana
Address	300 Longwood Ave
Email	boryana.petrova@childrens.harvard.edu
Phone	6173557433
Submit Date	2021-09-14
Raw Data File Type(s)	raw(Thermo)
Analysis Type Detail	LC-MS
Release Date	2022-08-29
Release Version	1

Select appropriate tab below to view additional metadata details:

Treatment:

Treatment ID:	TR002068
Treatment Summary:	Control AAV-GFP, MTX, AAV-SOD3 + buffers from Study Design. The pAAV-IRES-hrGFP vector was purchased from Agilent Technologies (240075) and pcDNA3.1-myc HisA (-)/ human SOD3 (myc-his tag at C-terminal) (36). Virus production and purification were performed by the Viral Core at BCH according to standard procedures (37). CD-1 mice (6-8 weeks) or Sprague Dawley rats (8 weeks) were given a single intravenous injection of 75 mg/kg MTX (Fisher Scientific, AAJ66364MD) dissolved in 0.9 % NaCl (Mountainside Medical, 0409-4888-10). MTX was freshly prepared for each experiment. MTX in mouse serum or CSF was assessed by MTX ELISA according to the manufacturer's instructions (Enzo Life Sciences, 142-0001).

Treatment ID:

TR002068

Treatment Summary:

Control AAV-GFP, MTX, AAV-SOD3 + buffers from Study Design. The pAAV-IRES-hrGFP vector was purchased from Agilent Technologies (240075) and pcDNA3.1-myc HisA (-)/ human SOD3 (myc-his tag at C-terminal) (36). Virus production and purification were performed by the Viral Core at BCH according to standard procedures (37). CD-1 mice (6-8 weeks) or Sprague Dawley rats (8 weeks) were given a single intravenous injection of 75 mg/kg MTX (Fisher Scientific, AAJ66364MD) dissolved in 0.9 % NaCl (Mountainside Medical, 0409-4888-10). MTX was freshly prepared for each experiment. MTX in mouse serum or CSF was assessed by MTX ELISA according to the manufacturer's instructions (Enzo Life Sciences, 142-0001).